[go: up one dir, main page]

EA201791321A1 - Составы ингибитора lfa-1 - Google Patents

Составы ингибитора lfa-1

Info

Publication number
EA201791321A1
EA201791321A1 EA201791321A EA201791321A EA201791321A1 EA 201791321 A1 EA201791321 A1 EA 201791321A1 EA 201791321 A EA201791321 A EA 201791321A EA 201791321 A EA201791321 A EA 201791321A EA 201791321 A1 EA201791321 A1 EA 201791321A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
lfa
inhibitor
formula
methods
Prior art date
Application number
EA201791321A
Other languages
English (en)
Inventor
Мэри Ньюман
Уилльям Ханке
Original Assignee
Саркоуд Байосайенс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50979140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201791321(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Саркоуд Байосайенс Инк. filed Critical Саркоуд Байосайенс Инк.
Publication of EA201791321A1 publication Critical patent/EA201791321A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к композициям, способам и наборам для лечения заболеваний "сухой глаз". В частности, в настоящем описании раскрыты стабилизированные фармацевтические композиции, содержащие соединение формулы 1, для различных видов применения, включая лечение синдрома сухого глаза. В одном из аспектов описаны способы и ингредиенты для улучшения стабильности композиций соединения формулы 1.
EA201791321A 2012-12-19 2013-12-18 Составы ингибитора lfa-1 EA201791321A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261739609P 2012-12-19 2012-12-19
US201361758147P 2013-01-29 2013-01-29

Publications (1)

Publication Number Publication Date
EA201791321A1 true EA201791321A1 (ru) 2018-04-30

Family

ID=50979140

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201591180A EA028008B1 (ru) 2012-12-19 2013-12-18 Составы ингибитора lfa-1
EA201791321A EA201791321A1 (ru) 2012-12-19 2013-12-18 Составы ингибитора lfa-1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201591180A EA028008B1 (ru) 2012-12-19 2013-12-18 Составы ингибитора lfa-1

Country Status (20)

Country Link
US (2) US11058677B2 (ru)
EP (2) EP3827823A1 (ru)
JP (1) JP6373867B2 (ru)
KR (1) KR101891144B1 (ru)
CN (1) CN104955453B (ru)
AU (1) AU2013361579B2 (ru)
BR (1) BR112015014367B1 (ru)
CA (1) CA2894170C (ru)
DK (1) DK2934510T3 (ru)
EA (2) EA028008B1 (ru)
ES (1) ES2846724T3 (ru)
HU (1) HUE052299T2 (ru)
IL (1) IL239490B (ru)
MX (2) MX368876B (ru)
NZ (1) NZ708821A (ru)
PL (1) PL2934510T3 (ru)
PT (1) PT2934510T (ru)
SI (1) SI2934510T1 (ru)
WO (1) WO2014100135A1 (ru)
ZA (2) ZA201504404B (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106995439B (zh) * 2016-01-26 2019-09-20 镇江圣安医药有限公司 氘取代3-(甲磺酰基)-l-苯丙氨酸衍生物及其药物组合物、药物制剂和用途
WO2019171260A1 (en) * 2018-03-09 2019-09-12 Mankind Pharma Ltd. Pharmaceutical composition of lifitegrast
EP3955926A4 (en) * 2019-04-18 2022-11-30 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders
EP3842032A1 (en) 2019-12-24 2021-06-30 Warszawskie Zaklady Farmaceutyczne Polfa S.A. A pharmaceutical formulation
CN116211796A (zh) * 2022-12-30 2023-06-06 新领先(重庆)医药科技有限公司 一种立他司特滴眼液及其制备方法
KR20240109779A (ko) * 2023-01-05 2024-07-12 주식회사 종근당 리피테그라스트와 토코페롤을 함유하는 건성안 예방 또는 치료용 약제학적 조성물
KR20250033790A (ko) 2023-09-01 2025-03-10 주식회사 와이에스생명과학 리피테그라스트 함유 점안 조성물
WO2025093739A1 (en) 2023-11-02 2025-05-08 Novaliq Gmbh Semifluorinated alkane compositions comprising lifitegrast
US20250161294A1 (en) * 2023-11-17 2025-05-22 Bausch + Lomb Ireland Limited Compositions and methods for treatment of ocular disorders
CN117771174A (zh) * 2023-12-29 2024-03-29 山东新时代药业有限公司 一种立他司特滴眼液及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2694719A (en) 1949-02-12 1954-11-16 Opplt Jan Method of stabilizing ascorbic acid with alkali-thiosulfate-carbamide-complexes
ATE147619T1 (de) * 1992-05-13 1997-02-15 Sandoz Ag Opthalmische zusammensetzungen enthaltend ein cyclosporin
US5429819A (en) * 1992-10-14 1995-07-04 Matsushita Electric Industrial Co., Ltd. Antiviral composition
IT1277707B1 (it) * 1995-12-22 1997-11-11 Chemedica Sa Formulazione oftalmica a base di ialuronato di sodio per uso nella chirurgia oculare
JP4138910B2 (ja) * 1997-07-02 2008-08-27 帝國製薬株式会社 経皮吸収性が良好で且つ皮膚刺激性の少ない塩酸アゼラスチン含有経皮製剤
RU2149611C1 (ru) * 1998-04-06 2000-05-27 Московская медицинская академия им. И.М. Сеченова Капли для лечения воспалительных заболеваний глаз (варианты)
DE19954516A1 (de) * 1999-11-12 2001-05-17 Boehringer Ingelheim Int Epinastin-haltige Lösungen
US6258814B1 (en) * 2000-10-13 2001-07-10 Schering Corporation Method of using cetirizine and pharmaceutical compositions containing the same for inducing sleep
US8877168B1 (en) * 2002-07-31 2014-11-04 Senju Pharmaceuticals Co., Ltd. Aqueous liquid preparations and light-stabilized aqueous liquid preparations
EP1651195A4 (en) * 2003-07-11 2007-10-03 Myriad Genetics Inc PHARMACEUTICAL PROCESSES, DOSIERSCHEMATA AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER DISEASE
FI119361B (fi) 2003-09-26 2008-10-31 Raute Oyj Menetelmä viilun sorvaamiseksi
US20060073172A1 (en) * 2004-10-01 2006-04-06 Schneider L W Stabilized ophthalmic solution for the treatment of glaucoma and lowering intraocular pressure
HUE031979T2 (en) * 2005-05-17 2017-08-28 Sarcode Bioscience Inc Preparations and methods for treating eye disorders
KR20080038335A (ko) * 2005-07-08 2008-05-06 센주 세이야꾸 가부시키가이샤 올로파타딘을 포함하는 경피 흡수 안과 제제
US7544893B2 (en) 2007-07-25 2009-06-09 Thomas & Betts International, Inc. Extruded wire duct end cap
ITRM20080182A1 (it) * 2008-04-07 2009-10-08 Medivis S R L Preparato oftalmico a base di dorzolamide e latanoprost per il trattamento topico del glaucoma.
EP2265124A4 (en) * 2008-04-15 2011-12-28 Sarcode Bioscience Inc AEROSOLISED LFA-1 ANTAGONISTS FOR THE USE IN THE LOCAL TREATMENT OF IMMUNE DISEASES
WO2009139817A2 (en) * 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
EP2265125B1 (en) 2008-04-15 2019-08-14 SARcode Bioscience Inc. Topical lfa-1 antagonists for use in localized treatment of immune related disorders
WO2010033800A2 (en) * 2008-09-19 2010-03-25 Alacrity Biosciences, Inc. Tetracycline stabilizing formulations
US20110212142A1 (en) * 2008-11-17 2011-09-01 Laila Pharmaceuticals Pvt.Ltd. Curcuminoids and its metabolites for the application in ocular diseases
JP5659388B2 (ja) * 2009-06-10 2015-01-28 マイトテック ソシエテ アノニム 医学及び獣医眼科の使用のための医薬組成物
KR20110001103A (ko) * 2009-06-29 2011-01-06 에스케이케미칼주식회사 보관 안정성이 향상된 톨테로딘 함유 경피 투여 조성물
MX2012005968A (es) * 2009-11-23 2012-08-15 Allergan Inc 7- [3,5 - dihidroxi - 2 - (3 - hidroxi - 5 - fenil - 1 - enil) - ciclopentil] - n - etil - hept - 5 - enamida (bmato prost) en la forma cristalina ii, metodos de preparacion y metodos para uso del mismo.
US20120190653A1 (en) * 2011-01-20 2012-07-26 Dow Pharmaceutical Sciences, Inc. Therapeutic eye drop comprising doxycycline and a stabilizer
US20130317058A1 (en) * 2011-02-18 2013-11-28 M/S. Appasamy Associates Ophthalmic composition for enabling dilation of pupils
RU2014102493A (ru) * 2011-06-29 2015-08-10 Аллерган, Инк. Алкафтадин для применения при лечении уртикарии
EP4420725A3 (en) * 2012-03-29 2025-04-16 Epion Therapeutics, Inc. Ocular treatment solutions, delivery devices and delivery augmentation methods
CN103230583A (zh) * 2013-05-17 2013-08-07 江西省创欣药业集团有限公司 兽用治疗肠道疾病的烟酸诺氟沙星复方注射液及制备方法

Also Published As

Publication number Publication date
MX391620B (es) 2025-03-19
ZA201608069B (en) 2017-11-29
WO2014100135A1 (en) 2014-06-26
IL239490A0 (en) 2015-08-31
CN104955453A (zh) 2015-09-30
JP6373867B2 (ja) 2018-08-15
HK1214536A1 (zh) 2016-07-29
MX368876B (es) 2019-10-21
DK2934510T3 (da) 2021-01-25
BR112015014367B1 (pt) 2022-11-22
MX2019012375A (es) 2020-01-20
SI2934510T1 (sl) 2021-02-26
CA2894170A1 (en) 2014-06-26
EP2934510A4 (en) 2016-08-17
HK1214963A1 (en) 2016-08-12
US11058677B2 (en) 2021-07-13
EP2934510B1 (en) 2020-10-28
US20150320737A1 (en) 2015-11-12
KR101891144B1 (ko) 2018-08-23
HUE052299T2 (hu) 2021-04-28
EA028008B1 (ru) 2017-09-29
CN104955453B (zh) 2018-09-18
AU2013361579B2 (en) 2018-05-24
EA201591180A1 (ru) 2015-12-30
MX2015007540A (es) 2016-04-13
IL239490B (en) 2018-12-31
ES2846724T3 (es) 2021-07-29
NZ708821A (en) 2020-03-27
EP3827823A1 (en) 2021-06-02
BR112015014367A2 (pt) 2017-07-11
JP2016503058A (ja) 2016-02-01
EP2934510A1 (en) 2015-10-28
PT2934510T (pt) 2021-01-13
PL2934510T3 (pl) 2021-07-05
US20220000859A1 (en) 2022-01-06
KR20150100763A (ko) 2015-09-02
AU2013361579A1 (en) 2015-06-18
ZA201504404B (en) 2020-01-29
CA2894170C (en) 2021-08-10

Similar Documents

Publication Publication Date Title
EA201791321A1 (ru) Составы ингибитора lfa-1
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MD20130095A2 (ru) Конденсированные соединения бензоксазепинонов в качестве модуляторов ионных каналов
UA110612C2 (ru) Производные 1-амино-2-циклопропилетилбороновои кислоты
EA201500953A1 (ru) 3-ацетиламино-1-(фенилгетероариламинокарбонил или фенилгетероарилкарбониламино)бензольные производные для лечения гиперпролиферативных нарушений
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
EA201692506A2 (ru) Ингибиторы репликации вирусов гриппа
EA201792421A1 (ru) Амидозамещенные производные циклогексана
MD20150043A2 (ru) Ингибиторы гистон деметилаз
EA201500653A1 (ru) Композиции, содержащие триазольное соединение
EA201290919A1 (ru) Индазольные соединения и их применение
EA201692166A1 (ru) Гетероциклические ингибиторы глютаминазы
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
EA201200176A1 (ru) Производные оксазина и их применение для лечения неврологических нарушений
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
EA201490103A1 (ru) Гидроксиметиларилзамещенные пирролотриазины в качестве ингибиторов alk1
EA201400976A1 (ru) Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена
EA201400311A1 (ru) Аминозамещенные имидазопиридазины
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
ATE555116T1 (de) Ahcy-hydrolasehemmer zur behandlung von hyperhomocysteinämie
EA201600434A1 (ru) Применение производных бензимидазолпролина
EA201590475A1 (ru) Тетрациклиновые соединения
EA201791432A1 (ru) Композиции на основе пролекарства монометилфумарата